quinacrine has been researched along with (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Balogh, Z; Fóris, G; Fülöp, P; Kassai, A; Kosztáczky, B; Paragh, G; Seres, I; Varga, Z | 1 |
1 other study(ies) available for quinacrine and (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
| Article | Year |
|---|---|
The association between angiotensin II-induced free radical generation and membrane fluidity in neutrophils of patients with metabolic syndrome.
Topics: Adult; Angiotensin I; Angiotensin II; Anticholesteremic Agents; Cholesterol; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Fatty Acids, Monounsaturated; Female; Fluvastatin; Homeostasis; Humans; Hypercholesterolemia; Indoles; Leukotriene C4; Male; Membrane Fluidity; Metabolic Syndrome; Middle Aged; Neutrophils; Pertussis Toxin; Protein Prenylation; Quinacrine; Signal Transduction; Superoxides; Vasoconstrictor Agents; Vasodilator Agents; Verapamil | 2006 |